Cyclosporin A: Drug discontinuation for the management of long-term toxicity after liver transplantation

Hepatology

Volumn 24, Issue 5, 1996, Pages 1085-1089

  Chan, Cho Yu ^a   DasGupta, Kathleen ^a   Baker, Alfred L ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Liver Study Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLOSPORIN A; DIURETIC AGENT; METHYLPREDNISOLONE; OKT 3; ORTHOCLONE; PREDNISONE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GRAFT REJECTION; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER BIOPSY; LIVER TOXICITY; LIVER TRANSPLANTATION; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSORY NEUROPATHY;

EID: 0029909950     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008903380     Document Type: Article

References (21)

1. Myers BD, Sibley R, Newton L, Tomlanovich S, Boshkos C, Stinson E, Luettscher JA, et al. The long-term course of cyclosporin-associated chronic nephropathy. Kidney Int 1988;33:590-600.
2. Calne RY, Wood AJ. Cyclosporin in cadaveric renal transplantation: three year follow-up of a European multi-centre trial [Letter]. Lancet 1985;2: 549.
3. O'Grady JG, Forbes A, Rolles K, Caine RY, Williams R. An analysis of cyclosporin efficacy and toxicity after liver transplantation. Transplantation 1988;45:575-579.
4. Chapman JR, Griffiths D, Harding NGL, Morris PJ. Reversibility of cyclosporin nephrotoxicity after three months treatment. Lancet 1985;1: 128-130.
5. Canafax DM, Martel EJ, Ascher NL, Payne WD, Sutherland DER, Simmons RL, Najarian JS. Two methods of managing cyclosporin nephrotoxicity: conversion to azathioprine, prednisone, or cyclosporin, azathioprine, and prednisone. Transplant Proc 1985;17:1176-1177.
6. Tegzess AM, Donker AJM, Meijer S, Van Son WJ, Van der Woude JF, Sluiter WJ, Sloof MJH, et al. Improvement in renal function after conversion from cyclosporin to prednisone/azathioprine in renal transplant patients. Transplant Proc 1985;17:1191-1193.
7. Chapman JR, Morris PJ. Cyclosporin nephrotoxicity and the consequences of conversion of azathioprine. Transplant Proc 1985;17:254-260.
8. Rocher LL, Milford EL, Kirman RL, Carpenter CB, Tilney NL. Utility of azathioprine in management of renal allograft recipients initially treated with cyclosporin. Transplant Proc 1985;17:1127-1230.
9. Flechner SM, Van Buren CT, Jarowenki M, Kerman R, Kahan BD. The fate of patient converted from cyclosporin to azathioprine to improve renal function. Transplant Proc 1985;17:1227-1230.
10. MacDonald AS, Belitcky P, Gupta R, Bitter-Suermann H, Campbell R, Cohen A, Lannon SG. Conversion from cyclosporin to azathioprine in renal graft recipients. Transplant Proc 1985;17:1940-1942.
11. Sandborn WJ, Hay JE, Porayko MK, Gores GJ, Steers JL, Krom RA, Wiesner RH. Cyclosporin withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. HEPATOLOGY 1994;19:924-932.
12. Ho K, Lasner B, Emond J, Baker A. Prior esophageal variceal bleeding does not adversely affect survival following orthotopic liver transplantation. HEPATOLOGY 1993;18:66-72.
13. Ludwig J, Demetris AJ, Ascher N, Batts KP, Ferrell L, Fung J, Hart J, et al. Terminology for hepatic allograft rejection. HEPATOLOGY 1995;22:648-654.
14. Lucas VP, Ponge TD, Plougastel-Lucase ML, Glemain P, Hourmant M, Soulillou JP. Musculoskeletal pain in renal-transplant recipients [Letter]. N Engl J Med 1991;325:1449-1450.
15. Feutren G, Mason J. Serum creatinine or glomerular filtration rate for monitoring cyclosporin therapy. Lancet 1991;338:1017.
16. Krom AF, Gips CH, Houthoff HJ, Newton D, Waaij DVD, Beelen J, Haagsma EB, et al. Orthotopic liver transplantation in Groningen, The Netherlands (1979-1983). HEPATOLOGY 1984;4:61S-65S.
17. Present D, Korelitz B, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. N Engl J Med 1980; 302:981-987.
18. Korelitz B, Present D. Shortcomings of the national Crohn's disease study: the exclusion of azathioprine without adequate trial. Gastroenterology 1981;80:193-200.
19. Brogan M, Hiserodt J, Oliver M, Stevens R, Korelitz B, Targan S. The effects of 6-mercaptopurine on natural killer-cell activities in Crohn's disease. J Clin Immunol 1985;5:204-211.
20. Hoffmann-Fezer G, Gall C, Zengerie U, Jranz B, Thierfelder S. Immunohistology and immunocytology of human t-cell chimerism and graft-versus-host disease in SCID mice. Blood 1993;81:3440-3448.
21. Starzl TE, Trucco M, Zeevi A, Kovoca M, Ildstad S, Demetris AJ, Ramos H, et al. Systemic chimerism in human female recipients of male livers. Lancet 1992;340:876-877.